Sonntag, 1. August 2021
Navigation öffnen
Anzeige:
Imfinzi NSCLC
Imfinzi NSCLC
JOURNAL ONKOLOGIE – STUDIE

Phase III Study of MR-Guided Focused Ultrasound Surgery for the Treatment of Uterine Fibroids Compared to Myomectomy

Rekrutierend

NCT-Nummer:
NCT03948789

Studienbeginn:
Juli 2020

Letztes Update:
11.09.2020

Wirkstoff:
-

Indikation (Clinical Trials):
Leiomyoma, Myofibroma

Geschlecht:
Frauen

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 3

Sponsor:
Krankenhaus Nordwest

Collaborator:
-

Studienleiter

Thorsten O Götze, PD Dr. med.
Principal Investigator
Krankenhaus Nordwest

Kontakt

Studienlocations
(3 von 4)

Alle anzeigen

Studien-Informationen

Brief Summary:

The aim of the study is to answer the question, whether in patients with symptomatic and medically not sufficiently treatable uterine fibroids (population) the "Magnetic-Resonance-Guided Focused Ultrasound Surgery" short, MRgFUS-TUF (intervention) offers less burdensome therapy and patient-relevant advantages (symptom relief) compared to the operative myomectomy (comparison). The study will hence investigate the therapeutic benefit of this method.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Women with symptomatic and medically untreatable uterine fibroids who score at least 40 points on the Symptom Severity Score (SSS) of the Uterine Fibroid Symptom and Quality of Life Questionnaire (UFS- QoL )

- Safe access for the MRgFUS possible (anatomical position of the fibroids): Pelvic magnetic resonance imaging to document the number, location and size of fibroids and to exclude malignancy and other pelvic pathologies; necessary to determine whether MRgFUS can be performed technically (presence of a stable ultrasound window and exclusion of scars in the access path)

- ≤ 5 fibroids requiring treatment

- Fibroids with a diameter ≤ 10 cm

- Total myoma volume ≤ 400 ml

- Patient is suitable for treatment with MRgFUS-TUF as well as for myomectomy

- Desire for least invasive treatment

- Indication for hysteroscopy and fractionated abrasion depending on the bleeding pattern and endometrial thickness and structure have been critically tested in advance.

- inconspicuous cytological smear of the cervix uteri not older than 12 months

- No previous uterine surgery / intervention

- Female patients aged> 18 years. Patients of reproductive age must adhere to appropriate contraception until 6 months after the procedure. (Methods of contraception that meet the criteria of highly effective contraception in the sense of the Note for guidance on non- clinical safety studies for the conduct of human clinical trials for meet pharmaceuticals [CPMP / ICH / 286/95 mod ]). Patients of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment.

- Karnofsky index ≥ 70

- Given medical operability

- Written consent of the patient

Exclusion Criteria:

- Pretreatment with ulipristal acetate ( Esmya ) ≤ 2 months

- Suspected Malignancy (absolute)

- Pregnancy (absolute)

- acute inflammatory process (absolute)

- Uterus myomatosis with more than 5 fibroids (relative, case-by-case decision)

- Uterine fibroids with a diameter over 10 cm (absolute)

- insufficient sound window can be reached for treatment (eg intestinal overlays, large scars in the acoustic window, very dorsal position of the fibroid)

- subserous stalked fibroids

- Inaccessible location of fibroids

- Scarring in the treatment area

- Recurring abortions

- general contraindications to MR contrast agents

- MRI contraindications

- Presence of pacemaker or metal implants

- Karnofsky Index <70

- Severe hepatic dysfunction (Aspartat-Aminotransferase (AST) / Transaminasen Alanin-Amino-transferase (ALT)> 3.5x ULN (upper limit of normal), Alkalische Phosphatase (AP)> 6xULN)

- Active CHD (congenital heart disease), (symptoms present), cardiomyopathy or heart failure in NYHA (New York Heart Association) and EF (ejection fraction) stage III-IV <45%

- Serious internistic side-diseases or an acute infection

- Chronic inflammatory bowel disease

- Pregnancy or lactation

- Participation in another interventional study

Studien-Rationale

Primary outcome:

1. WAI question 4 (Time Frame - Until at least three consecutive days questionnaire was answered as indicated, up to 12 months):
Time to sustainably return to normal activities, based on the daily Work Activity Index (WAI) dimension, "Estimated Impairment of Disease Performance". The return to normal activities is considered to be given if the question "Hindrance of medical condition or injury at work?" (min max: 1: 'in my opinion, I am completely unable to work', 6: 'No Disability') is answered for at least three consecutive days with "No Disability" (6) or "I can do my job, but have complaints" (5).

2. Symptom Severity Score of the UFS-QoL (Time Frame - 12 months after treatment):
The symptom severity is determined to be the co- primary endpoint for assessing therapeutic efficacy, based on the SSS (Symptom Severity Score) of the UFS-QoL (Uterine fibroid symptom and quality of life questionnaire). The co-primary assessment is performed 12 months after the primary treatment and for the evaluation the proportion of patients with at least 25 points improvement in the SSS is determined (0-100 scale, 100 indicating very strong symptoms, 0 no or low symptoms).

Secondary outcome:

1. Hospital stay in days (Time Frame - 12 months after treatment)

2. Pain according to visual analog scale (Time Frame - 12 months after treatment):
Visual analog scale ranges from 0-100, 0 indicating no pain, 100 severe pain

3. Number of Adverse Events (AEs) (Time Frame - 12 months after treatment)

4. Number of postinterventional/postsurgery treatment complications (Time Frame - 12 months after treatment)

5. Number of re-interventions (Time Frame - 12 months after treatment)

6. Alleviation of symptoms (irregular period, unfulfilled wish for child, pain, quality of life according to UFS-QoL (Time Frame - 12 months after treatment):
QoL: Quality of Life score regarding symptoms, ranges from 0-100, 0 indicating very low QoL, 100 indicating very high QoL

7. Health related quality of life according to UFS-QoL (Time Frame - 12 months after treatment):
QoL: Quality of Life score regarding health, ranges from 0-100, 0 indicating very low QoL, 100 indicating very high QoL

8. Sexuality related parameters according to UFS-QoL (Time Frame - 12 months after treatment):
QoL: Quality of Life score regarding sexuality, ranges from 0-100, 0 indicating very low QoL, 100 indicating very high QoL

9. Number of pregnancies and live births (Time Frame - 12 months after treatment)

10. Number of late complications like venous thromboembolisms within Follow up time frame (Time Frame - 12 months after treatment)

11. Number of fibroid recurrences (de novo fibroids) within Follow up time frame (Time Frame - 12 months after treatment)

12. Time period until return to normal physical activities, measured by the rate of patients, who achieved an a priori clinically relevant reduction of SSS of UFS-QoL (Time Frame - 12 months after treatment):
at timepoints: months 1, 3 and 6 compared to baseline.

Studien-Arme

  • Active Comparator: A Myomectomy
    Removement of uterine fibroids by myomectomy
  • Experimental: B MRgFUS-TUF
    Removement of uterine fibroids by Magnetic Resonance Imaging-controlled high-focussed ultrasound therapy (MRgFUS-TUF)

Geprüfte Regime

  • Magnetic Resonance Imaging-controlled high-focussed ultrasound therapy:
    Magnetic Resonance Imaging-controlled high-focussed ultrasound
  • Myomectomy (laparoscopic or open surgical):
    Myomectomy (laparoscopic or open surgical)

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
EHA 2021
  • SCD: Häufigere und längere VOC-bedingte Krankenhausaufenthalte nach Vorgeschichte von VOC-Hospitalisierungen – Ergebnisse einer Beobachtungsstudie
  • Real-World-Daten des ERNEST-Registers untermauern Überlebensvorteil unter Ruxolitinib bei primärer und sekundärer Myelofibrose
  • I-WISh-Studie: Ärzte sehen TPO-RAs als beste Option, um anhaltende Remissionen bei ITP-Patienten zu erzielen
  • Phase-III-Studie REACH2 bei steroidrefraktärer akuter GvHD: Hohes Ansprechen auf Ruxolitinib auch nach Crossover
  • SCD: Neues digitales Schmerztagebuch zur tagesaktuellen Erfassung von VOCs wird in Beobachtungsstudie geprüft
  • Französische Real-World-Studie: Eltrombopag meist frühzeitig nach ITP-Diagnose im Rahmen eines Off-label-Use eingesetzt
  • Fortgeschrittene systemische Mastozytose: Französische Real-World-Studie bestätigt klinische Studiendaten zur Wirksamkeit von Midostaurin
  • CML-Management weitgehend leitliniengerecht, aber verbesserungsfähig – Ergebnisse einer Querschnittsbefragung bei britischen Hämatologen
  • Britische Real-World-Studie: Kardiovaskuläres Risikomanagement bei MPN-Patienten in der Primärversorgung nicht optimal
  • Myelofibrose: Früher Einsatz von Ruxolitinib unabhängig vom Ausmaß der Knochenmarkfibrose